Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
View Top Employees from Vir Biotechnology, Inc.Website | http://www.vir.bio |
Ticker | VIR |
Revenue | $2.3 billion |
Funding | $250 million |
Employees | 601 (601 on RocketReach) |
Founded | 2016 |
Address | 1800 Owens St Suite 900, San Francisco, California 94158, US |
Phone | (415) 906-4324 |
Technologies |
JavaScript,
HTML,
Google Analytics
+68 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Drug Discovery, Health Care, Science and Engineering, Medical |
Keywords | Biotechnology, Therapeutic Activities, Infectious Disease Treatments, Hiv Treatment, Respiratory Conditions |
Competitors | Atara Biotherapeutics, Biohaven Pharmaceutical Holding Company, Ltd, Dendreon, Dynavax Technologies, NGM Biopharmaceuticals |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325414 Companies, NAICS Code 325413 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Vir Biotechnology, Inc. employee's phone or email?
The Vir Biotechnology, Inc. annual revenue was $2.3 billion in 2024.
Marianne De Backer is the CEO of Vir Biotechnology, Inc..
601 people are employed at Vir Biotechnology, Inc..
Vir Biotechnology, Inc. is based in San Francisco, California.
The NAICS codes for Vir Biotechnology, Inc. are [3254, 325414, 325413, 325, 32541, 32].
The SIC codes for Vir Biotechnology, Inc. are [283, 28].